The efficacy of Eli Lilly and Company’s tirzepatide appears likely to outweigh concerns about adverse events and treatment discontinuations in patients taking it for type 2 diabetes on top of insulin products, at least at the lower dose levels.
The Indianapolis-based drug maker announced positive data from the Phase III SURPASS-3 and SURPASS-5 clinical trials on 17 February. The...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)